scholarly journals Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study

2022 ◽  
Author(s):  
Anne Dib ◽  
Florence Chartier ◽  
Katharina Ihle ◽  
Isabelle Jamonneau ◽  
Lisa Ludwig ◽  
...  
2019 ◽  
Vol 7 (6) ◽  
pp. 46-50
Author(s):  
Eva Dewi Purba ◽  
Khairunnisa M ◽  
Hasibuan Poppy Anjelisa

Objective: The aim of this study was to assess the drug-related problems (DRPs) in Type 2 diabetes mellitus(T2DM) patients whom also diagnosed with hypertension. Methods: The retrospective study was conducted from October to December 2018 at Doloksanggul Hospital in North Sumatera, Indonesia involving 42 T2DM with hypertension patients according to research inclusion criteria. The assessment of DRPs was based on the Pharmaceutical Care Network Europe (PCNE) tools version 8.01. Results: This study identified 41 DRPs, averaging 0.98±0.24 DRPs per patient. The majority of problems were treatment effectiveness problems 97.62% (41 patients) while the patient related was the main causes (47.24%). The most intervention was conducted at patient level (71.62%).Conclusion: Early detection of DRPs by pharmacist are essential to prevent DRPs and to ensure the effectiveness of drug therapy.  


2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Kenichi Tanaka ◽  
Yosuke Okada ◽  
Akemi Tokutsu ◽  
Yoshiya Tanaka

AbstractReal-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82). We used stabilized propensity score-based inverse probability of treatment weighting (IPTW) to reduce selection bias and confounding by observed covariates. Changes in glycated hemoglobin (HbA1c) at the end of the 12-month treatment were evaluated. After adjustment by stabilized propensity score-based IPTW, no significant differences were observed in patient characteristics between the liraglutide and dulaglutide groups. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.4%; dulaglutide, 8.7 to 7.5%). Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents. High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. The effects of liraglutide and dulaglutide on lowering HbA1c levels at 12 months were comparable in a real-world setting.


2021 ◽  
Author(s):  
Kenichi Tanaka ◽  
Yosuke Okada ◽  
Akemi Tokutsu ◽  
Yoshiya Tanaka

Abstract Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n=97; dulaglutide, n=82). Changes in glycated hemoglobin (HbA1c) at the end of 12-month treatment were evaluated. Compared with the liraglutide group, the dulaglutide group included significantly older patients with longer disease duration, lower body mass index, and higher proportion of dementia cases. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.6%; dulaglutide, 8.8 to 7.5%). Hierarchical regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents, after adjustment for differences in patient characteristics and drug adjustments during the 12-month period. High baseline HbA1c, the addition of GLP-1 RA treatment, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. Although patient characteristics were different between the two treatment groups, comparable HbA1c-lowering effects were noted in real-world settings.


2018 ◽  
Vol 35 (11) ◽  
pp. 1605-1612 ◽  
Author(s):  
F. Gomez-Peralta ◽  
A. Lecube ◽  
A. Fernández-Mariño ◽  
I. Alonso Troncoso ◽  
C. Morales ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document